Date: 2014-10-10
Type of information: Initiation of preclinical development
phase: 1-2
Announcement: presentation of results at IDWeek 2014™ taking place Oct. 8-12, 2014 in Philadelphia, Pennsylvania
Company: Pfizer (USA - NY)
Product: 4-antigen Staphylococcus aureus candidate vaccine (SA4Ag)
Action mechanism:
Disease: Staphylococcus aureus infection
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On October 10, 2014, Pfizer announced that it will present data from a Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer’s investigational 4-antigen Staphylococcus aureus (S. aureus) candidate vaccine (SA4Ag) in healthy adults. The data will be presented at IDWeek 2014™ taking place Oct. 8-12, 2014 in Philadelphia, Pennsylvania. The study results demonstrate that SA4Ag was well tolerated in the 456 healthy adults 18 to 64 years old who randomly received a single intramuscular injection of SA4Ag or placebo. The study also showed rapid rises in functional antibody titers against S. aureus that were maintained through at least 12 months. The SA4Ag vaccine candidate (PF-06290510), currently in Phase 2 clinical trials, was granted Fast Track designation by the FDA in February 2014.
